NEUROCRINE BIOSCIENCES INC (NBIX)
Sector: Health Care
2026 Annual Meeting Analysis
NEUROCRINE BIOSCIENCES INC · Meeting: May 27, 2026
Directors FOR
3
Directors AGAINST
0
Say on Pay
FOR
Auditor
AGAINST
Director Elections
Election of Class III Directors
Dr. Gorman has served since 2008 and brings deep company knowledge as former CEO; NBIX's 3-year total shareholder return of +27.3% outperforms the disclosed peer group median of +23.6% by +3.7 percentage points, well below the 65-point threshold needed to trigger an against vote, and no overboarding, attendance, or independence concerns apply.
Mr. Lyons has served since 1993 and contributes extensive biotech leadership experience as former CEO; the company's strong positive 3-year return clears the peer-group performance test by a wide margin, and no overboarding, attendance, or independence concerns are identified.
Ms. Mercier joined in April 2021, bringing senior commercialization expertise from Gilead Sciences and Bristol-Myers Squibb; she is independent, attended at least 75% of meetings, and the company's TSR performance does not trigger any concern under the policy.
All three Class III nominees pass every policy screen: no overboarding, all attended at least 75% of meetings, all are independent (or appropriately classified), and NBIX's 3-year total shareholder return of +27.3% outperforms the disclosed peer group median by +3.7 percentage points, far short of the 65-percentage-point gap required to trigger a negative vote under the strong-positive-TSR tier. Vote FOR all three.
Say on Pay
✓ FORCEO
Kyle W. Gano, Ph.D.
Total Comp
$13,448,935
Prior Support
over 90%%
The company received over 90% shareholder support on say-on-pay in each of the last three years, well above the 70% threshold that would require a response. CEO total compensation of approximately $13.4 million is consistent with benchmarks for a CEO at a large-cap ($13.2B market cap) specialty biopharmaceutical company, and the compensation structure emphasizes equity-based variable pay, aligning executive rewards with long-term stock performance. The company's 3-year total shareholder return of +27.3% outperforms both the disclosed peer group median (+23.6%) and the XBI ETF benchmark, supporting the conclusion that above-benchmark incentive pay, if any, is justified by shareholder outcomes. The company also maintains a clawback policy, further supporting a FOR vote.
Auditor Ratification
✗ AGAINSTAuditor
Ernst & Young LLP
Tenure
34 yrs
Audit Fees
$2,009,331
Non-Audit Fees
$716,987
Ernst & Young LLP has audited Neurocrine Biosciences since 1992 — a relationship of approximately 34 years — which exceeds the policy's 25-year tenure threshold. The non-audit fee ratio (tax fees of $716,987 divided by audit fees of $2,009,331) is approximately 36%, which is within the acceptable range, and there are no disclosed material restatements. However, the 34-year tenure is a clear trigger under the policy, and the proxy does not provide a specific and compelling rationale for continued engagement such as a disclosed multi-year rotation plan or other mitigating factors.
Overall Assessment
The 2026 NBIX annual meeting presents four proposals: all three Class III director nominees earn a FOR vote as the company's total shareholder return comfortably passes the peer-group performance test and no governance flags are present; auditor ratification earns an AGAINST vote solely because Ernst & Young's 34-year tenure far exceeds the policy's 25-year independence threshold without a compelling rationale for continuation; say-on-pay earns a FOR vote given consistent 90%+ shareholder support, a pay structure weighted toward variable equity, and stock performance that outpaces peers; the equity plan amendment falls outside current policy scope and receives no determination.
Compensation Peer Group
16 companies disclosed in 2026 proxy filing